Europe • Frankfurt Stock Exchange • FRA:SNW • FR0000120578
The current stock price of SNW.DE is 82.36 EUR. In the past month the price increased by 2.32%. In the past year, price decreased by -20.58%.
ChartMill assigns a technical rating of 1 / 10 to SNW.DE. When comparing the yearly performance of all stocks, SNW.DE is a bad performer in the overall market: 87.54% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to SNW.DE. SNW.DE has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months SNW.DE reported a non-GAAP Earnings per Share(EPS) of 7.82. The EPS increased by 1.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
29 analysts have analysed SNW.DE and the average price target is 100.48 EUR. This implies a price increase of 21.99% is expected in the next year compared to the current price of 82.36.
For the next year, analysts expect an EPS growth of 8.1% and a revenue growth 6.49% for SNW.DE
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.77 | 198.536B | ||
| 1SAN | SANOFI | 9.5 | 193.923B | ||
| MRK | MERCK KGAA | 14.58 | 54.587B | ||
| 1MRK | MERCK KGAA | 14.2 | 53.065B | ||
| UNC | UCB SA | 25.81 | 51.623B | ||
| UCB | UCB SA | 25.67 | 51.545B | ||
| 1BAYN | BAYER AG-REG | 9.48 | 45.486B | ||
| BAYN | BAYER AG-REG | 9.44 | 45.358B | ||
| IPN | IPSEN | 12.07 | 11.708B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
SANOFI
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE FR
Employees: 84587
Phone: 33153774000
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
The current stock price of SNW.DE is 82.36 EUR. The price increased by 2.54% in the last trading session.
SANOFI (SNW.DE) has a dividend yield of 5.08%. The yearly dividend amount is currently 3.79.
SNW.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SNW.DE.
The Revenue of SANOFI (SNW.DE) is expected to grow by 6.49% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
SANOFI (SNW.DE) has a market capitalization of 198.92B EUR. This makes SNW.DE a Large Cap stock.